Merck & Co has said it will not file its cholesterol drug anacetrapib with regulators, saying that trial results are not good enough for clinical filings. The news came in a brief statement ...

Remember CETP? It was a hot topic in cholesterol-lowering drug development a few years ago, but when Merck & Co finally pulled the plug on anacetrapib five years ago on lacklustre phase 3 data ...

Working solutions of anacetrapib used as an internal standard were prepared at concentrations of 10 μmol, 100 nmol, and 1 nmol per ml from a stock solution. Brain and liver samples were homogenized ...

Investing.com – U.S. stocks closed higher on Wednesday, as financials, mostly banks, surged on the back of rising ...

School of Pharmacy, University College Cork, College Road, Cork County, T12 R229 Cork , Ireland ...

Familial hypercholesterolemia results from gene mutations approximately halving the number of functional LDL receptors in heterozygotes and a greater lack in homozygotes. Reduced receptor-mediated ...

As I briefly mentioned earlier, Merck's anacetrapib and Pfizer's torcetrapib were potential blockbusters that were halted because of safety concerns or lack of meaningful cardiovascular benefits.

It is creating an oral low-dose inhibitor of cholesteryl ester transfer protein (CETP), anacetrapib. Due to a series of encouraging reports on the progress of its drug pipeline, analysts say the ...